Pulse Biosciences Inc. (NASDAQ: PLSE) appointed Liane Teplitsky as Chief Operating Officer and expanded Dr. David Kenigsberg's role to full-time Chief Medical Officer, according to a company statement.

As COO, Teplitsky will oversee clinical, regulatory, quality, and commercial functions. The company said both appointments support development of its nPulse Cardiac Catheter Ablation System for atrial fibrillation treatment.

Teplitsky brings 20 years of medical technology experience, including roles in electrophysiology and cardiovascular technologies. She previously served as CEO of Artedrone and held senior positions at Abbott Laboratories, St. Jude Medical, and Zimmer Biomet. She holds degrees from Duke University and the University of Saskatchewan.

Dr. Kenigsberg will maintain his clinical practice while expanding his leadership capacity as the company advances its IDE pivotal clinical study for the nPulse Cardiac Catheter System.

The company granted Teplitsky equity inducement awards consisting of stock options for 700,000 shares at $19.06 per share and restricted stock units for 200,000 shares. The awards include both time-based and performance-based vesting tied to market capitalization and revenue milestones.

Pulse Biosciences also awarded stock options for 7,700 shares to two other recent hires at the same exercise price of $19.06 per share, subject to four-year time-based vesting.

The Hayward, California-based company develops nanosecond pulsed field ablation technology for medical applications.